CXCR4 Antagonistic Polypeptide ALB408-423 for HIV and Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for HIV-1, cancer metastasis, and chronic inflammatory diseases like asthma and pulmonary fibrosis are limited in effectively targeting the CXCR4/CXCL12 interaction, which plays a critical role in disease progression, as existing therapies do not adequately inhibit viral infection or cancer cell migration mediated by this pathway.
Innovation Solution
A CXCR4 antagonistic polypeptide, ALB408-423, derived from human serum albumin, is developed to inhibit HIV-1 infection and block CXCL12-induced cellular responses by directly interacting with the CXCR4 receptor, preventing viral entry and cancer cell migration, along with its derivatives and associated diagnostic and therapeutic agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing therapies target the CXCR4/CXCL12 interaction, then some inhibition of viral infection or cancer cell migration is achieved, but the inhibition is insufficient for effective disease treatment
Solution Approach 1:
The patent modifies the chemical structure of CXCR4 antagonists by changing amino acid sequences, adding post-translational modifications (phosphorylation, glycosylation, sulfation), and creating derivatives with enhanced binding affinity and potency. This resolves the contradiction by optimizing the pharmacological parameters of the antagonist to achieve sufficient inhibition for effective disease treatment.
Solution Approach 2:
The invention creates composite peptide structures combining natural albumin fragments with synthetic modifications and conjugations. The polypeptide comprises multiple functional regions including the core antagonistic sequence (ALB408-423) combined with modifying groups and potential fusion proteins, achieving enhanced therapeutic efficacy through composite structural design.
2Reliability
If CXCR4 antagonists are used to block cancer cell migration, then metastasis is inhibited, but cytotoxicity or off-target effects may occur
Solution Approach 1:
The patent employs peptide-based CXCR4 antagonists that are rapidly degraded and excreted, minimizing accumulation and chronic toxicity. The short half-life of peptide fragments compared to small molecules reduces off-target effects and cumulative harmful factors while maintaining effective anti-metastatic activity during the treatment window.
Solution Approach 2:
The invention introduces targeted modifications at specific locations within the peptide sequence, such as N-terminal or C-terminal extensions, and creates isoforms with differentiated binding affinities. This allows optimization of anti-metastatic activity in specific tissue contexts while reducing cytotoxicity through localized structural variations that enhance selectivity.
3Ease of manufacture
If natural albumin fragments are used as CXCR4 antagonists, then therapeutic potential is identified, but the potency and specificity may be insufficient
Solution Approach 1:
The patent segments the albumin protein into specific functional fragments (ALB408-423 and derivatives) that contain the core CXCR4 binding motif. This segmentation isolates the active pharmacological region from the rest of the albumin structure, enabling enhanced potency through focused binding while maintaining ease of manufacture through peptide synthesis or controlled proteolytic cleavage.
Solution Approach 2:
The invention modifies the natural albumin fragment parameters by adding post-translational modifications (phosphorylation, glycosylation, sulfation) and creating chemical derivatives. These parameter changes enhance the binding affinity, specificity, and antagonistic potency of the fragment while preserving the manufacturability advantage of using a natural protein backbone.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
ALB408-423 effectively blocks X4-tropic HIV-1 and HIV-2 infections, suppresses cancer cell migration, and reduces inflammatory responses, offering a promising therapeutic and diagnostic tool for these diseases without inducing cytotoxicity.
Implementation Method 1
ALB408-423 specifically binds CXCR4 thereby preventing infection of CXCR4 tropic HIV-1 variants and binding of the natural CXCR4 agonist CXCL12
Implementation Method 2
Following interaction of CXCR4/CXCL12 intracellular calcium (Ca2+) ions fluxes are triggered. ALB408-423 blocks CXCL12-induced cellular responses
Data Source
AI summary
A peptide having the following amino acid sequence: Z1-LVRYTKKVPQVSTPTL-Z2(ALB-408) and its biologically active fragments and/or variants and/or derivatives, especially amidated, acetylated, sulfated, phosphorylated and/or glycosylated derivatives, and peptides obtainable by multiple synthesis which have the biological activity of ALB408-423; wherein Z represents number of from 0 to 10 amino acid residues.